Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AVITA Medical (RCEL) EBITDA Margin (2018 - 2025)

AVITA Medical (RCEL) has disclosed EBITDA Margin for 7 consecutive years, with 23.83% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 16267.0% year-over-year to 23.83%, compared with a TTM value of 4.8% through Dec 2025, up 1557.0%, and an annual FY2025 reading of 14.39%, up 592.0% over the prior year.
  • EBITDA Margin was 23.83% for Q4 2025 at AVITA Medical, up from 10.89% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 186.5% in Q4 2024 and bottomed at 154.95% in Q1 2024.
  • Average EBITDA Margin over 4 years is 27.88%, with a median of 66.04% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 9107bps in 2025, while the deepest fall reached -16267bps in 2025.
  • Year by year, EBITDA Margin stood at 169.28% in 2022, then dropped by -4bps to 161.79% in 2023, then rose by 15bps to 186.5% in 2024, then plummeted by -87bps to 23.83% in 2025.
  • Business Quant data shows EBITDA Margin for RCEL at 23.83% in Q4 2025, 10.89% in Q3 2025, and 61.17% in Q2 2025.